肿瘤药学2025，Vol.15Issue(1)：124-129,6.DOI:10.3969/j.issn.2095-1264.2025.01.17
高级别B细胞淋巴瘤伴C-myc/BCL2/BCL6重排患者三线格菲妥单抗单药挽救治疗1例
Third-line glofitamab monotherapy as salvage treatment for a patient with HGBL harboring C-myc/BCL2/BCL6 rearrangements:A case report
姚嘉瑞 1唐乐 1刘鹏1
作者信息
- 1. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院内科 抗肿瘤分子靶向药物临床研究北京市重点实验室,北京,100021
- 折叠
摘要
Abstract
Objective To evaluate the efficacy and safety of glofitamab as a later-line salvage therapy in patients with high-grade B-cell lymphoma(HGBL)harboring C-myc/BCL2/BCL6 rearrangements.Methods Using a case report inte-grated with literature analysis,we analyzed a 55-year-old female HGBL patient with C-myc/BCL2/BCL6 rearrangements who received third-line glofitamab(CD20×CD3 bispecific antibody).Results The patient underwent sequential frontline therapy consisting of an R-CHOP-like regimen followed by Pola-R-CHP for four cycles before developing disease progres-sion.Second-line therapy with R-DICE-like plus selinexor failed to achieve objective response.Given high tumor burden and suboptimal response to conventional chemotherapy,glofitamab was administered as third-line therapy,achieving par-tial response after three treatment cycles.Following initial glofitamab infusion,grade 2 cytokine release syndrome manifest-ed with high fever,which was managed by tocilizumab after dynamic monitoring of lymphocyte subsets and cytokine levels.Conclusion Glofitamab may provide clinical benefits in multi-drug resistant HGBL as a salvage therapy,but requires vigi-lant adverse event monitoring with intensive clinical surveillance.关键词
高级别B细胞淋巴瘤/C-myc/BCL2/BCL6重排/格菲妥单抗/疗效/安全性Key words
High-grade B-cell lymphoma/C-myc/BCL/BCL6 rearrangements/Glofitamab/Efficacy/Safety分类
临床医学引用本文复制引用
姚嘉瑞,唐乐,刘鹏..高级别B细胞淋巴瘤伴C-myc/BCL2/BCL6重排患者三线格菲妥单抗单药挽救治疗1例[J].肿瘤药学,2025,15(1):124-129,6.
